Name:	clvs_AdditionalPaymentDueToDefermentOfMilestonePayment
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Aggregate maximum possible milestone payments to be made on attaining sales targets.

No definition available.

Name:	clvs_AggregatePaymentToBeMadeOnAttainingSalesTarget
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents the amount of deferred milestone payment agreed to be paid within the specified period.

No definition available.

Name:	clvs_DeferredMilestonePayment
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Maximum potential development regulatory milestone payments to be made in the future if regulatory and other milestones are met.

No definition available.

Name:	clvs_FutureExpectedDevelopmentRegulatoryAndSalesMilestonePayments
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of annual sales target above which the majority of the sales milestone payments must be made.

No definition available.

Name:	clvs_FutureExpectedRegulatoryAndDevelopmentPayment
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of cash payments incurred to license the use and development of a drug product from the licensor. The upfront payments are expensed to acquired in process research and development if it is determined that the in-licensed product does not have an alternative future use at the time the in-license agreement is executed.

No definition available.

Name:	clvs_InLicensingArrangementCostsUpFrontPayment
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Maximum collaboration development costs reimbursable.

No definition available.

Name:	clvs_MaximumCollaborationDevelopmentCostsReimbursable
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of acquired in process research and development milestones paid to Pfizer prior to FDA approval of Rucaparib.

No definition available.

Name:	clvs_MilestonesPaidPriorToFdaApproval
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the minimum number of chemotherapy treatments necessary for determination if a patient is eligible for Rubraca tablets.

No definition available.

Name:	clvs_MinimumNumberOfChemotherapies
Namespace Prefix:	clvs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the maximum number of months after the FDA approval for Rubraca (rucaparib) tablets upon which payment will be made to counterparty.

No definition available.

Name:	clvs_NumberOfMonthsAfterDateOfFdaApproval
Namespace Prefix:	clvs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Reductions in research and development expense for reimbursable development costs.

No definition available.

Name:	clvs_ReductionsInResearchAndDevelopmentExpenseForReimbursableDevelopmentCosts
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Milestone payments under in-licensing agreements.

No definition available.

Name:	clvs_SalesMilestonePaymentsUnderInLicensingAgreements
Namespace Prefix:	clvs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.

No definition available.

Name:	us-gaap_AccountsAndOtherReceivablesNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Name:	clvs_LicenseAgreementsTypeAxis=clvs_LicenseAgreementsLucitanibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	clvs_LicenseAgreementsLicensorsNameAxis=clvs_LicenseAgreementsLicensorPfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	clvs_LicenseAgreementsTypeAxis=clvs_LicenseAgreementsRucaparibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	clvs_LicenseAgreementsLicensorsNameAxis=clvs_LicenseAgreementsLicensorAstraZenecaUKLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: